A Study to Investigate LYL797 in Adults With Solid Tumors

- ≥ 18 years of age at time of informed consent

- Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable that is ROR1+ by central laboratory immunohistochemistry (IHC)

- Measurable disease including a target lesion and an additional lesion for biopsy

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Adequate organ and marrow function

- Women of childbearing potential must have a negative pregnancy test at screening

- All participants must agree to practice highly effective methods of contraception

- Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy

- Prior solid organ transplantation

- Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed

- Untreated or active infection at the time of screening or leukapheresis

- HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis

- Impaired cardiac function or clinically significant cardiac disease

- Uncontrolled pleural or pericardial effusion

- Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis

- Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors

- Pregnant or lactating/nursing women